David Scheinberg

About

David Scheinberg, MD, PhD, is the Chair of the Center for Experimental Therapeutics at Memorial Sloan Kettering Cancer Center and the Deputy Director of the Sloan Kettering Institute for Therapeutic Discovery. His laboratory's overall goals are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action and resistance. His research includes the development of antibodies, targeted nano-devices, engineered cells, and active specific agents such as vaccines, with an emphasis on translating these therapies into human clinical trials. Notable contributions include the development of targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, and humanized antibodies, all of which have reached human clinical trials. His team has also discovered TCR mimic antibodies to intracellular proteins, prototype targeted nano-machines, and cellular micropharmacies. Dr. Scheinberg specializes in caring for patients with leukemia and advancing new treatment strategies through innovative research.

Research topics

• Biology
• Computational biology
• Immunology
• Cancer research
• Biochemistry
• Genetics
• Cell biology
• Chemistry
• Medicine

Selected publications

• Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

  Cancer Discovery · 2020 · 158 citations

  .

  DOI

• Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA

  Nature Medicine · 2022 · 123 citations

  Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes derived from recurrently mutated driver genes. Here we describe a high-throughput platform combining single-cell transcriptomic and T cell receptor (TCR) sequencing to establish whether mutant PIK3CA, among the most frequently genomically altered driver oncogenes, generates an immunogenic public NeoAg. Using this strategy, we developed a panel of TCRs that recognize an endogenously processed neopeptide encomp…

  DOI

• Engineering CAR-T cells to activate small-molecule drugs in situ

  Nature Chemical Biology · 2021 · 76 citations

  Senior authorCorresponding
  DOI

• Design of high-specificity binders for peptide–MHC-I complexes

  Science · 2025-07-24 · 41 citations

  articleOpen access

  Class I major histocompatibility complex (MHC-I) molecules present peptides derived from intracellular antigens on the cell surface for immune surveillance. Proteins that recognize peptide-MHC-I (pMHCI) complexes with specificity for diseased cells could have considerable therapeutic utility. Specificity requires recognition of outward-facing amino acid residues within the disease-associated peptide as well as avoidance of extensive contacts with ubiquitously expressed MHC. We used RFdiffusion t…

  PublisherDOI

• Metabolic engineering to facilitate anti-tumor immunity

  Cancer Cell · 2025-02-27 · 21 citations

  articleOpen access
  PublisherOA PDFDOI

Recent grants

• Project 4: Using Synthetic Immunology to Improve Activity and Specificity, and Overcome Resistance, in Cellular Therapy

  NIH · $138.0M · 1997–2025

• Understanding and Mimicking TCR Recognition with Therapeutic Monoclonal Antibodies.

  NIH · $6.1M · 2020–2027

• NIH Grant U01CA058260

  NIH · $937k · 1996

Frequent coauthors

• Tao Dao

  Memorial Sloan Kettering Cancer Center

  195 shared

• Michael R. McDevitt

  Memorial Sloan Kettering Cancer Center

  181 shared

• Ron S. Gejman

  139 shared

• Christopher M. Bourne

  University of Pennsylvania

  138 shared

• Joseph G. Jurcic

  130 shared

• Martin G. Klatt

  Charité - Universitätsmedizin Berlin

  118 shared

• Megan M. Dacek

  115 shared

• Stanley R. Frankel

  113 shared

Labs

• The David Scheinberg LabPI

Similar researchers at Cornell University

• John Blenish-128
• Omar Abdel-Wahabh-118
• Ingo Mellinghoffh-105